Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
December 1, 2016

Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune

Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers in Israel.

Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers in Israel.

According to the agreement, Teva Pharma will be responsible for marketing and distribution of the inhaler in Israel.

The agreement enables the two partners to introduce medical cannabis for pain management.

Boston Children’s Hospital and GE Health Care have entered an agreement to develop advanced digital solutions to detect paediatric brain disorders.

Pursuant to the same agreement, the two partners will jointly work on development and commercialisation of diagnosis and treatments for childhood brain diseases.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

MedImmune and Abpro Corporation have entered a collaborative agreement to a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor.

According to the agreement, Abpro's subsidary AbMed will be responsible for global development and commercialisation of the novel antibody candidate and MedImmune will receive payments during the drugs development, regulatory and sales milestone and additional royalties.

The agreement enables the two partners to explore different potential areas for bispecific antibody.

"Boston Children’s Hospital and GE Health Care have entered an agreement to develop advanced digital solutions to detect paediatric brain disorders."

Catalent plans to raise $400m through the private placement of senior unsecured notes due 2024. The offer will be subscribed to by institutional buyers.

The company plans to invest the funds to acquire Accucaps Industries, to repay the debts and for certain general corporate purposes.

Innovent Biologics has raised $260m in a series D venture financing round led by Future Industries Investment Fund (FIIF) and co-led by China Life Insurance and other blue chip investors.

The company plans to use the funds to further advance the development of product pipeline and expand its manufacturing capacity.


Image: Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers. 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU